Literature DB >> 9398735

A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.

R M Hofstra1, O Fattoruso, L Quadro, Y Wu, A Libroia, U Verga, V Colantuoni, C H Buys.   

Abstract

Specific mutations in the ret protooncogene have been found associated with multiple endocrine neoplasia type 2A (MEN 2A) and type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). Mutations in one of five cysteine residues in the extracellular domain have been found in over 95% of families with MEN 2A and 88% of families with FMTC. In MEN 2B patients, a specific mutation at codon 918, substituting a threonine for a methionine, has been found in 95% of cases. In FMTC, in addition to the mutations of the extracellular cysteines, three intracellular base pair changes have been reported at codons 768 and 804. Here we describe a novel intracellular mutation in exon 15 of the ret gene that leads to the substitution of an alanine for a serine at codon 891 in a family with medullary thyroid carcinoma. This amino acid change may be important in determining substrate specificity or, alternatively, may play a role in ATP binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398735     DOI: 10.1210/jcem.82.12.4439

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

3.  Does a somatic deletion in RET clarify the sporadic nature of medullary thyroid carcinoma?

Authors:  O Gimm; D J Marsh
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

4.  Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.

Authors:  X-P Qi; R-B Ying; J-M Ma; W-T Liu; Z-F Du; J Fei; C-P Yang; Q-Z Song; H-Y Jin; Z-G Chen; J-S Han; J-Q Wang; X-L Chen; Y Zhao; J-J Lu; X-N Zhang
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

5.  Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.

Authors:  S Dvorakova; E Vaclavikova; J Duskova; P Vlcek; A Ryska; B Bendlova
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

Review 6.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 7.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

8.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Authors:  F Lesueur; M Corbex; J D McKay; J Lima; P Soares; P Griseri; J Burgess; I Ceccherini; S Landolfi; M Papotti; A Amorim; D E Goldgar; G Romeo
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

Review 9.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

10.  A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation.

Authors:  Jinhyang Jung; Shinya Uchino; Youngha Lee; Hoyong Park
Journal:  J Korean Med Sci       Date:  2010-01-21       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.